BCL2 and cancer: Moreover, Maritoclax was reported to sensitise a number of cancer cell lines to ABT-737 (first generation BH3 mimetic which inhibits BCL-2, BCL-XL and BCL-w) by down-regulating MCL-1 (Doi et al. 2012).